Navigation Links
Cancer Centers of North Carolina Offers HDR Brachytherapy for Treatment of Cancerous Tumors
Date:8/5/2009

RALEIGH, N.C., Aug. 5 /PRNewswire/ -- Cancer Centers of North Carolina, an affiliate of US Oncology, Inc., continues to offer cutting-edge treatment options to its patients through the addition of High Dose Rate (HDR) brachytherapy. This latest advance in brachytherapy allows physicians to deliver precise radiation treatment to a patient's cancerous tumor and is rapidly becoming the treatment of choice for certain types of cancer.

With HDR brachytherapy, radiation is delivered directly to the cancer target through the use of catheters, needles or applicators inserted into a body cavity or directly into the tumor. A computer-controlled delivery system is used to optimize the dose distribution to the target. As a result of this precise delivery, the surrounding healthy tissue and critical organs are preferentially spared from high doses of radiation and side effects may be reduced.

Unlike low dose rate brachytherapy treatment, HDR therapy can be delivered on an outpatient basis at Cancer Centers of North Carolina's office, which incorporates all patient needs in one central location. In addition, treatment times for HDR brachytherapy are typically 10-15 minutes in duration instead of several days that are required for low dose rate brachytherapy. Cancer Centers of North Carolina is currently administering HDR primarily on breast and gynecologic cancers.

The HDR brachytherapy program at Cancer Centers of North Carolina is directed by its board-certified radiation oncologists, Dr. John Reilly and Dr. Kolby Sidhu. "HDR brachytherapy is a very effective addition to our fight against cancer. This technique delivers a high dose of radiation directly to the area of disease," according to Dr. Reilly. Dr. Sidhu adds, "Cancer patients benefit by having more treatment options. There is also the potential benefit for a shorter course of treatment, particularly for breast cancer patients being treated with Mammosite(R)."

About Cancer Centers of North Carolina

Cancer Centers of North Carolina (CCNC) has been providing comprehensive cancer care in the greater Triangle area for 30 years. Beginning as a single physician practice, originally named Raleigh Hematology Oncology, CCNC has grown to a physician staff of thirteen medical oncologists, two radiation oncologists, a head and neck surgical oncologist and a gynecologic oncologist, and offers services in Raleigh, North Raleigh, Cary, Clayton, and Dunn. The practice provides advanced state-of-the-art diagnostic and therapeutic services including administration of chemotherapy, biologic and targeted therapies, Computed Tomography (CT), Intensity Modulated Radiation Therapy (IMRT), laboratory and pharmacy services, and an extensive clinical trials program connecting patients to leading cancer investigators around the country. CCNC brings the best of medical science and cancer care support services together in one pleasant, convenient, community- based organization. For more information, visit www.cancercentersofnc.com

CCNC is united in healing with US Oncology, supporting the nation's foremost cancer treatment and research network to accelerate the availability and use of evidence-based medicine and shared best practices. With more than 1,227 physicians treating more than 650,000 patients at 468 locations in 39 states, the US Oncology network and CCNC provide cancer patients with access to the latest advancements in therapies, clinical research and technology, as well as best-in-class clinical and operational processes that help to advance the quality, safety and cost effectiveness of cancer care. For more information, visit www.usoncology.com.


'/>"/>
SOURCE US Oncology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... AVACEN Medical , Inc. (AVACEN) announced that ... New Product Innovation Award for Its fibromyalgia pain management ... medical device market research by Frost & Sullivan,s industry experts. ... pain relief product, the AVACEN 100, offers a safe and ... pain. ...
(Date:10/11/2017)...  Caris Life Sciences ® , a leading innovator ... precision medicine, today announced that St. Jude Medical Center,s ... (POA) as its 17 th member. Through participation ... Cancer Institute will help develop standards of care and ... making cancer treatment more precise and effective. ...
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical Services, ... solutions for injectable drug administration, today shared the results ... Adapter for improving the intradermal administration of polio vaccines. ... Vaccination Summit in May 2017 by Dr. Ondrej ... Department, World Health Organization (WHO), and recently published in ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of ... its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his ... July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, ... guideline updates for the primary prevention of cardiovascular diseases during the 15th ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids ... sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited ... all ages; it is a non-competitive, non-timed event, which is all about having fun ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
Breaking Medicine News(10 mins):